Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | TNF | P01375 | 1/20 | 0.41 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.41 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.41 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6794948 | 0.77 | RAB9A (0.51) | NPC1RAB9AKMT2ACYP3A4DPP4 | |
| SCHEMBL29499010 | 0.75 | NPC1 (0.58) | NPC1RAB9AKMT2ACYP3A4DPP4 | |
| SCHEMBL9952997 | 0.72 | ALDH1A1 (0.55) | NPC1RAB9AKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL6797484 | 0.70 | POLB (0.72) | RAB9AKMT2ASMN1; SMN2ALDH1A1CYP1A2 | |
| SCHEMBL12789801 | 0.65 | MEN1 (0.64) | NPC1RAB9AKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL29499005 | 0.65 | NPC1 (0.64) | NPC1RAB9AKMT2ACYP3A4SMN1; SMN2 | |
| SCHEMBL9954631 | 0.64 | KMT2A (0.46) | KMT2ACYP3A4SMN1; SMN2ALDH1A1CYP1A2 | |
| SCHEMBL1064761 | 0.64 | HDAC1 (0.79) | NPC1KMT2ASMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL31241042 | 0.64 | MAPK8 (0.47) | KMT2AALDH1A1MEN1HTTMAPT | |
| SCHEMBL9953607 | 0.63 | KMT2A (0.58) | KMT2ACYP3A4ALDH1A1CYP1A2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6747035-B2 | ANTIINFLAMMATORY AGENTS; ANTIALLERGENS | WARNER-LAMBERT LLC | 2004-06-08 | — | — | US | disclosed |
| EP-1419159-A1 | 1-ALKYL 0R 1-CYCLOALKYLTRIAZOLO 4,3-A]QUINAZOLIN-5-ONES AS PHOSPHODIESTERASE INHIBITORS | Warner-Lambert Company LLC (US) | 2004-05-19 | — | — | EP | disclosed |
| US-20030069260-A1 | 1-alkyl or 1-cycloalkyltriazolo[4,3-a]quinazolin-5-ones as phosphodiesterase inhibitors | GUADILLIERE BERNARD (FR) | 2003-04-10 | — | — | US | disclosed |
| WO-2003016314-A1 | 1-ALKYL 0R 1-CYCLOALKYLTRIAZOLO[4,3-A]QUINAZOLIN-5-ONES AS PHOSPHODIESTERASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2003-02-27 | — | — | WO | disclosed |
| EP-1285922-A1 | 1-Alkyl or 1-cycloalkyltriazolo[4,3-a]quinazolin-5-ones as phosphodiesterase inhibitors | WARNER-LAMBERT COMPANY (US) | 2003-02-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069260-A1 | 1-alkyl or 1-cycloalkyltriazolo[4,3-a]quinazolin-5-ones as phosphodiesterase inhibitors | PDE3A, PDE4A, PDE5A | NPC1 2456/4885RAB9A 2106/4885KMT2A 2500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.